Figures & data
Figure 1. Amniotic fluid secreted phospholipase A2 concentrations (sPLA2) in women at term with clear amniotic fluid and MSAF. Patients with MSAF had a significantly higher median amniotic fluid secreted phospholipase A2 concentration (ng/mL) than those with clear amniotic fluid [1.7 (1–2.9) versus 0.3 (0–0.6); p < 0.001].
![Figure 1. Amniotic fluid secreted phospholipase A2 concentrations (sPLA2) in women at term with clear amniotic fluid and MSAF. Patients with MSAF had a significantly higher median amniotic fluid secreted phospholipase A2 concentration (ng/mL) than those with clear amniotic fluid [1.7 (1–2.9) versus 0.3 (0–0.6); p < 0.001].](/cms/asset/bd05166e-51ab-44f2-857d-ebafa1b01140/ijmf_a_847918_f0001_b.jpg)
Figure 2. Amniotic fluid secreted phospholipase A2 concentration (sPLA2) among women with MSAF at term with presence and absence of endotoxin or microorganisms. Patients with MSAF and intra-amniotic inflammation/infection at term had a significantly higher median secreted phospholipase A2 concentration (ng/mL) than those without intra-amniotic inflammation/infection [2.4 (1.7–6.99) versus 1.7 (1.3–2.5); p = 0.049].
![Figure 2. Amniotic fluid secreted phospholipase A2 concentration (sPLA2) among women with MSAF at term with presence and absence of endotoxin or microorganisms. Patients with MSAF and intra-amniotic inflammation/infection at term had a significantly higher median secreted phospholipase A2 concentration (ng/mL) than those without intra-amniotic inflammation/infection [2.4 (1.7–6.99) versus 1.7 (1.3–2.5); p = 0.049].](/cms/asset/6d791fe9-5ec5-471c-9796-4b1b7f777ea4/ijmf_a_847918_f0002_b.jpg)